SII to seek DCGI market nod for qHPV vaccine against cervical cancer
The Serum Institute of India (SII) has sought the government's permission to manufacture and stockpile indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer after the completion of the phase 2/3 clinical trials to ensure its early availability in the country, official sources said on Sunday. The firm will soon seek market authorisation as well as a manufacturing licence from the Drugs Controller General of India (DCGI) for the vaccine, they said.
The application mentions that every year, lakhs of women are diagnosed with cervical cancer and the death ratio is also very high. In India, cervical cancer ranks as the second most frequent cancer among women in the 15-44 age group.
For more details, check out the full story on the link below:
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)